Neostem (NBS) 6.46 $NBS
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
CEO Dr. Robin Smith of NeoStem to Discuss Agreement to Acquire California Stem Cell, Inc. Live Today on Clear Channel's "The Traders Network Show"
Marketwire - Tue Apr 15, 6:16AM CDT
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem"
, a leader in the emerging cellular therapy industry, announced today that Chairman and CEO, Dr. Robin Smith, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. In this exclusive 2-segement interview, Dr. Smith will go over the strategic details of their contract to acquire California Stem Cell, Inc. (CSC) .
Why NeoStem (NBS) Stock Is Up Today
at The Street - Mon Apr 14, 2:57PM CDT
NeoStem (NBS) shares are up 5.8% to $6.77 in trading on Monday
NeoStem Inc. "Continued Growth through Strategic Acquisitions"
ACCESSWIRE - Mon Apr 14, 9:16AM CDT
PITTSBURGH, PA / April 14, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc.
GlobeNewswire - Mon Apr 14, 6:11AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC" , an Irvine, California based stem cell biotechnology company. As a result of this acquisition, NeoStem plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence.
NeoStem Announces Conference Call and Webcast
GlobeNewswire - Fri Apr 11, 3:14PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that it plans to conduct a conference call and webcast. The call and webcast will be on Monday, April 14, at 10:00 AM EDT. To access the webcast, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events or call 1-855-235-8282 and provide Conference ID 29328201.
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
NeoStem, Inc. "An Update from Dr. Robin Smith, Chairman and CEO"
ACCESSWIRE - Mon Apr 07, 9:17AM CDT
PITTSBURGH, PA/ ACCESSWIRE / April 7th, 2014 NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
BTV-Business Television - Neostem Developing Cell Based Therapeutics to Prevent, Treat or Cure Disease
Newsfile Corp - Fri Apr 04, 1:00PM CDT
full story)
NeoStem Welcomes Dr. Adel Nada as Vice President, Immunotherapy
GlobeNewswire - Thu Apr 03, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today the appointment of Dr. Adel Nada as Vice President, Immunotherapy. In this position, Dr. Nada will be responsible for developing the Company's T Regulatory Cell Program, which is investigating the use of T Regulatory Cells ("Tregs" to treat diseases caused by imbalances in the immune system. The Company plans to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in the third quarter of 2014, as well as a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.
BTV Highlights Life Sciences with Amgen, Aurora Spine and NeoStem
Marketwire - Thu Apr 03, 5:01AM CDT
BTV goes on location to bring investors stories on emerging companies for their portfolio.
NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple April Conferences
GlobeNewswire - Tue Apr 01, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in April.
NeoStem Congratulates Lee Clough on Winning Award From American Society for Apheresis
GlobeNewswire - Mon Mar 31, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that Lee Clough, RN, HP (ASCP), Director of Clinical Affairs & Apheresis for Progenitor Cell Therapy (PCT), a wholly-owned subsidiary of NeoStem, has been awarded the SHS Award from the American Society for Apheresis (ASFA). Ms. Clough will be presented with the award at the ASFA Annual Business Meeting Luncheon in San Francisco, CA on April 4, 2014.
NeoStem Begins Research Collaboration for Treatment of Skin Wounds in Scleroderma
GlobeNewswire - Wed Mar 26, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, today announced that it has signed an agreement for a research collaboration investigating the potential of very small embryonic-like stem cells ("VSELs(TM)" in treating difficult to heal wounds in an animal model of scleroderma.
NeoStem to Present at ARM's Regen Med Investor Day and BioCentury's Future Leaders in the Biotech Industry Conference
GlobeNewswire - Wed Mar 19, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, announced today that the Company will present at three sessions at the Alliance for Regenerative Medicine (ARM) 2nd Annual Regen Med Investor Day, to be held on March 26, 2014. Additionally, Dr. Robin Smith, Chairman and CEO of NeoStem, will be presenting at BioCentury's 21 Annual Future Leaders in the Biotech Industry conference, to be held on March 28, 2014. Both conferences will take place in New York City.
Cord Blood Banking Services Market 2013 - 2019: Private and Public Cord Blood Banks
M2 - Tue Mar 18, 10:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bj2tzf/cord_blood) has announced the addition of the "Cord Blood Banking Services Market 2013 - 2019: Private and Public Cord Blood Banks" report to their offering. The market overview section of the report includes the qualitative analysis of the overall market in terms of drivers, restraints and opportunities, various disease conditions treated and treatable from cord blood, regulatory framework, along with the Porter's five forces analysis and market attractiveness analysis. The report is concluded with the competitive landscape and profiling of some of the major cord blood banks located worldwide. Some of such cord blood banks profiled in the report include: - Cord Blood Registry Systems, Inc. - Cord Blood America, Inc. - NeoStem, Inc. - Cryo-Cell International, Inc - China Cord Blood Corporation - ViaCord, Inc. Based on the types of banks that store cord blood, the global cord blood banking services market is classified into public cord blood banks and private cord blood banks. This report studies the current market competition and future growth of private and public cord blood banks in terms of revenue generation of such services (USD Million) for the period 2011 - 2019. The report also demonstrates the compounded annual growth rate (CAGR %) for each such service type for the forecast period 2013 - 2019 while considering 2012 as the base year. Geographically, this report categorizes the global cord blood banking services market into four regions namely North America, Europe, Asia-Pacific and rest of the world. An analysis of the market size and future potential of public and private cord blood banks has been analysed for each of the four regional markets. A qualitative study of the various major countries in each of these regions has been included in the report. Scope of the Report: Type of Service Vendor - Private cord blood banks - Public cord blood banks Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Cord Blood Banking Services Market Overview Chapter 4 Global Cord Blood Banking Services Market, by Storage Options, 2011 - 2019 (USD Billion) Chapter 5 Global Cord Blood Banking Services Market, by Geography, Size and Forecast, 2011 - 2019 (USD Billion) Chapter 6 Recommendations Chapter 7 Company Profiles - China Cord Blood Corporation - Cord Blood America, Inc. - Cord Blood Registry Systems, Inc. - Cordlife Group Ltd. - Cryo-Cell International, Inc. - Cryo-Save Group AV - NeoStem, Inc. - ViaCord, Inc. For more information visit http://www.researchandmarkets.com/research/bj2tzf/cord_blood
NeoStem Reports Fourth Data Safety Monitoring Board Review of PreSERVE AMI Trial
GlobeNewswire - Mon Mar 17, 6:40AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" , a leader in the emerging cellular therapy industry, today announced that, on March 11, 2014, the Data Safety Monitoring Board ("DSMB" recommended continuing the PreSERVE AMI Phase 2 clinical trial following a fourth interim data and safety review. The PreSERVE trial of AMR-001 is a Phase 2, randomized, placebo controlled, double-blind study designed to enroll 160 patients. AMR-001 is being evaluated for the preservation of heart function after a severe heart attack. Full enrollment has been completed for the trial and data will be available in the second half of 2014.
NeoStem Announces 2013 Year End Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 13, 3:30PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company" today announced 2013 year end results and provided an update on its business.
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
CEO Dr. Robin Smith of NeoStem to Discuss Agreement to Acquire California Stem Cell, Inc. Live Today on Clear Channel's "The Traders Network Show"
Marketwire - Tue Apr 15, 6:16AM CDT
NeoStem, Inc. (NASDAQ: NBS) ("NeoStem"
, a leader in the emerging cellular therapy industry, announced today that Chairman and CEO, Dr. Robin Smith, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. In this exclusive 2-segement interview, Dr. Smith will go over the strategic details of their contract to acquire California Stem Cell, Inc. (CSC) . Why NeoStem (NBS) Stock Is Up Today
at The Street - Mon Apr 14, 2:57PM CDT
NeoStem (NBS) shares are up 5.8% to $6.77 in trading on Monday
NeoStem Inc. "Continued Growth through Strategic Acquisitions"
ACCESSWIRE - Mon Apr 14, 9:16AM CDT
PITTSBURGH, PA / April 14, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc.
GlobeNewswire - Mon Apr 14, 6:11AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC" , an Irvine, California based stem cell biotechnology company. As a result of this acquisition, NeoStem plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence. NeoStem Announces Conference Call and Webcast
GlobeNewswire - Fri Apr 11, 3:14PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that it plans to conduct a conference call and webcast. The call and webcast will be on Monday, April 14, at 10:00 AM EDT. To access the webcast, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events or call 1-855-235-8282 and provide Conference ID 29328201. Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
NeoStem, Inc. "An Update from Dr. Robin Smith, Chairman and CEO"
ACCESSWIRE - Mon Apr 07, 9:17AM CDT
PITTSBURGH, PA/ ACCESSWIRE / April 7th, 2014 NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Dr. Robin Smith. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
BTV-Business Television - Neostem Developing Cell Based Therapeutics to Prevent, Treat or Cure Disease
Newsfile Corp - Fri Apr 04, 1:00PM CDT
full story)
NeoStem Welcomes Dr. Adel Nada as Vice President, Immunotherapy
GlobeNewswire - Thu Apr 03, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today the appointment of Dr. Adel Nada as Vice President, Immunotherapy. In this position, Dr. Nada will be responsible for developing the Company's T Regulatory Cell Program, which is investigating the use of T Regulatory Cells ("Tregs" to treat diseases caused by imbalances in the immune system. The Company plans to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in the third quarter of 2014, as well as a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014. BTV Highlights Life Sciences with Amgen, Aurora Spine and NeoStem
Marketwire - Thu Apr 03, 5:01AM CDT
BTV goes on location to bring investors stories on emerging companies for their portfolio.
NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple April Conferences
GlobeNewswire - Tue Apr 01, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT" , will present at multiple upcoming conferences in April. NeoStem Congratulates Lee Clough on Winning Award From American Society for Apheresis
GlobeNewswire - Mon Mar 31, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that Lee Clough, RN, HP (ASCP), Director of Clinical Affairs & Apheresis for Progenitor Cell Therapy (PCT), a wholly-owned subsidiary of NeoStem, has been awarded the SHS Award from the American Society for Apheresis (ASFA). Ms. Clough will be presented with the award at the ASFA Annual Business Meeting Luncheon in San Francisco, CA on April 4, 2014. NeoStem Begins Research Collaboration for Treatment of Skin Wounds in Scleroderma
GlobeNewswire - Wed Mar 26, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, today announced that it has signed an agreement for a research collaboration investigating the potential of very small embryonic-like stem cells ("VSELs(TM)" in treating difficult to heal wounds in an animal model of scleroderma. NeoStem to Present at ARM's Regen Med Investor Day and BioCentury's Future Leaders in the Biotech Industry Conference
GlobeNewswire - Wed Mar 19, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, announced today that the Company will present at three sessions at the Alliance for Regenerative Medicine (ARM) 2nd Annual Regen Med Investor Day, to be held on March 26, 2014. Additionally, Dr. Robin Smith, Chairman and CEO of NeoStem, will be presenting at BioCentury's 21 Annual Future Leaders in the Biotech Industry conference, to be held on March 28, 2014. Both conferences will take place in New York City. Cord Blood Banking Services Market 2013 - 2019: Private and Public Cord Blood Banks
M2 - Tue Mar 18, 10:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bj2tzf/cord_blood) has announced the addition of the "Cord Blood Banking Services Market 2013 - 2019: Private and Public Cord Blood Banks" report to their offering. The market overview section of the report includes the qualitative analysis of the overall market in terms of drivers, restraints and opportunities, various disease conditions treated and treatable from cord blood, regulatory framework, along with the Porter's five forces analysis and market attractiveness analysis. The report is concluded with the competitive landscape and profiling of some of the major cord blood banks located worldwide. Some of such cord blood banks profiled in the report include: - Cord Blood Registry Systems, Inc. - Cord Blood America, Inc. - NeoStem, Inc. - Cryo-Cell International, Inc - China Cord Blood Corporation - ViaCord, Inc. Based on the types of banks that store cord blood, the global cord blood banking services market is classified into public cord blood banks and private cord blood banks. This report studies the current market competition and future growth of private and public cord blood banks in terms of revenue generation of such services (USD Million) for the period 2011 - 2019. The report also demonstrates the compounded annual growth rate (CAGR %) for each such service type for the forecast period 2013 - 2019 while considering 2012 as the base year. Geographically, this report categorizes the global cord blood banking services market into four regions namely North America, Europe, Asia-Pacific and rest of the world. An analysis of the market size and future potential of public and private cord blood banks has been analysed for each of the four regional markets. A qualitative study of the various major countries in each of these regions has been included in the report. Scope of the Report: Type of Service Vendor - Private cord blood banks - Public cord blood banks Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Cord Blood Banking Services Market Overview Chapter 4 Global Cord Blood Banking Services Market, by Storage Options, 2011 - 2019 (USD Billion) Chapter 5 Global Cord Blood Banking Services Market, by Geography, Size and Forecast, 2011 - 2019 (USD Billion) Chapter 6 Recommendations Chapter 7 Company Profiles - China Cord Blood Corporation - Cord Blood America, Inc. - Cord Blood Registry Systems, Inc. - Cordlife Group Ltd. - Cryo-Cell International, Inc. - Cryo-Save Group AV - NeoStem, Inc. - ViaCord, Inc. For more information visit http://www.researchandmarkets.com/research/bj2tzf/cord_blood
NeoStem Reports Fourth Data Safety Monitoring Board Review of PreSERVE AMI Trial
GlobeNewswire - Mon Mar 17, 6:40AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
, a leader in the emerging cellular therapy industry, today announced that, on March 11, 2014, the Data Safety Monitoring Board ("DSMB" recommended continuing the PreSERVE AMI Phase 2 clinical trial following a fourth interim data and safety review. The PreSERVE trial of AMR-001 is a Phase 2, randomized, placebo controlled, double-blind study designed to enroll 160 patients. AMR-001 is being evaluated for the preservation of heart function after a severe heart attack. Full enrollment has been completed for the trial and data will be available in the second half of 2014. NeoStem Announces 2013 Year End Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 13, 3:30PM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"
today announced 2013 year end results and provided an update on its business. 
